MindMaze Therapeutics, formed by the business combination of Relief Therapeutics and NeuroX, aims to redefine neurological care with innovative digital and pharmacological treatments.

Target Information

MindMaze Therapeutics Holding SA (SIX: MMTX), formed through the business combination of Relief Therapeutics Holding SA and NeuroX Group SA, is a pioneering company based in Switzerland. The newly established entity focuses on developing and commercializing innovative digital treatments for neurological diseases, integrating advanced technology to enhance patient care. MindMaze aims to bridge significant gaps in neurological rehabilitation through evidence-based treatments that facilitate patient recovery from diverse conditions, including stroke and Parkinson’s disease.

Industry Overview in Switzerland

The healthcare industry in Switzerland is globally recognized for its robust infrastructure and high standards of care, particularly in neurology. In recent years, the prevalence of neurological diseases has surged, with 1 in 6 people likely to develop such conditions due to aging populations. This dilemma has intensified the demand for innovative therapies and rehabilitation solutions that are both scalable and effective.

As traditional healthcare systems often fail to deliver adequate therapy options for neurological diseases, there is an urgent need for comprehensive solutions that combine both pharmacological and non-pharmacological approaches. The growth of digital health technolo